⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Organogenesis Holdings Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Organogenesis Holdings Inc.
↗Canton, USA
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care, surgical, and sports medicine markets. The company provides a comprehensive portfolio of innovative regenerative products designed to support patients across the continuum of care, from early wound healing to closure.
Headquartered in Canton, Massachusetts, the company is publicly traded on the NASDAQ under the ticker ORGO. Its product portfolio includes well-known brands such as Apligraf, Affinity, and PuraPly, which are utilized in various clinical settings to address complex patient needs in wound management and surgical biologics.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Founded:1985
Ownership:public
Status:operating
FUNDING
Total Raised:$330M
Investors:Avista Capital Partners
STOCK
Exchange:NASDAQ
Ticker:ORGO
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Cell therapy, Tissue engineering
Active Trials:0
Trial Phases:-
FDA Approvals:2
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:The Napoleon Hill Foundation (for business training/leadership)
COMPETITION
Position:Leader
LEADERSHIP
Key Executives:
Gary S. Gillheeney, Sr. - CEO
LINKS
Website:organo.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Organogenesis Holdings Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.